fhB7H3.CAR-Ts

Cell therapy

TThe Affiliated Hospital of Xuzhou Medical University

fhB7H3.CAR-Ts is one of 72 biologic programs targeting Liver Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Liver CancerPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 2

Bavencio

EMD Serono

Phase 3

7 3

Vepesid

AAvyxa

Phase 3

6 4

Naropin

FFresenius Kabi Oncology Ltd.

Phase 3

1 5

Tylenol

KKenvue Brands

Phase 3

1 6

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

1 7

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 8

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

3 9

TQB2450

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 10

SHR-A1921

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

Ovarian Cancer

NCT05211557

Q1 2027

Phase 1/2Recruiting

Liver Cancer

NCT05323201

Clinical

Trials by Indication[1]

Liver Cancer1 trial

Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1/2·NCT05323201·15 enrolled

Ovarian Cancer1 trial

Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1/2·NCT05211557·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for fhB7H3.CAR-Ts. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fhB7H3.CAR-Ts compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fhB7H3.CAR-Ts. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Hospital of Xuzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Company: TThe Affiliated Hospital of Xuzhou Medical University

fhB7H3.CAR-Ts

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2027

Trials by Indication[1]

Liver Cancer1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News